Tuesday - May 13, 2025
WILMINGTON, Del. / Mar 22, 2023 / Business Wire / Phreesia, Inc. (NYSE: PHR), a leader in patient intake, outreach and activation, today announced the appointment of Balaji Gandhi as Phreesia’s Chief Financial Officer. Gandhi will succeed Randy Rasmussen, effective March 24, 2023. Rasmussen will serve as a Strategic Advisor to the Company for a period of time, to facilitate a smooth transition of his responsibilities.
Gandhi has over 25 years of experience as an operating executive with healthcare services and technology companies and as an investment research analyst following the space. He joined Phreesia in 2019 in preparation for its initial public offering and most recently served as Senior Vice President, Investor Relations, and a member of the executive leadership team.
“Balaji’s extensive knowledge of Phreesia and experience successfully partnering with our leadership team uniquely qualify him to transition to the CFO role. Additionally, Balaji is an experienced public company executive with a proven track record of communicating effectively with the investment community,” said Chaim Indig, Chief Executive Officer and Co-Founder of Phreesia. “I look forward to continuing to work closely with Balaji as we execute on our near-term plan and drive long-term value for all of our stakeholders.”
“On behalf of Phreesia, I want to thank Randy for his leadership in establishing strong controls, systems and processes across our finance organization which has enabled us to scale as a public company over the past three years,” added Indig. “We wish him all the best in his future endeavors.”
ABOUT PHREESIA
Phreesia provides healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.
Last Trade: | US$25.98 |
Daily Change: | -0.07 -0.27 |
Daily Volume: | 93,724 |
Market Cap: | US$1.510B |
March 12, 2025 December 09, 2024 October 28, 2024 October 01, 2024 September 04, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load